BSX - Boston Scientific Corporation
A medical device innovator specializing in minimally invasive interventions across cardiology, urology, and endoscopy.
Finlify Score
33.9 / 100
Data Quality
PARTIAL
Penalty
-1.0
Sector
Health Care
Close Price
$46.76
-0.32%
52W Range
$45.99 - $109.50
Market Cap
$71.8B
-0.3%Compared to previous day
2026 Q1 Revenue
$5.2B
-1.6%Changes from last reporting quarter
2026 Q1 EPS
$0.00
Diluted shares
Analyst Rating
40 analysts in latest ratings feed
RSI
11.3
<40 oversold
2Y Range Position
1%
-57.3% from high / +1.7% from low
Beta
0.56
Relative to market benchmark
MACD
0.03
MACD line -2.71 / signal line -2.74
Fundamental Trend
Growth 30.4Financial Health
Quality 78.5Data Quality
PARTIALValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID33.9 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $5.2B-1.6% | $5.3B+4.4% | $5.1B+0.1% | $5.1B+8.5% |
| Gross Profit | $3.6B-1.8% | $3.7B+3.9% | $3.5B+3.5% | $3.4B+6.6% |
| Operating Income | $1.1B+33.5% | $825M-21.3% | $1.0B+28.0% | $819M-11.1% |
| Net Income | $1.3B+99.9% | $670M-11.3% | $755M-5.0% | $795M+18.3% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
The Finlify signal for BSX is AVOID, with a score of 34.9 out of 100, suggesting a cautious stance. This signal appears to be influenced by weaker technical momentum and fundamental trends, despite a relatively strong financial quality score, though it is important to note that data quality is PARTIAL, which may limit the full confidence in the signal.
Technical
The technical picture for BSX appears weak, with a very low Relative Strength score of 2.4/100. The asset has experienced significant recent declines, indicated by a -12.4% return over 20 days and a -34.2% return over 60 days, placing it -55.3% from its 52-week high. The RSI(14) at 29.1 suggests the stock may be in oversold territory.
Fundamentals
While Financial Quality appears strong at 78.5/100, the Fundamental Trend score is relatively low at 30.4/100, suggesting some underlying concerns. Valuation metrics show a P/E ratio of 24.1x, a P/B of 5.8x, and a P/S of 3.5x. The asset's Beta of 0.6 indicates it may be less volatile than the broader market.
Macro Context
The current macro environment, characterized by an elevated CPI YoY of 4.3% and a 10Y Treasury Yield at 4.5%, could present headwinds for growth-oriented companies like those in healthcare, potentially impacting valuation multiples and borrowing costs. The positive yield spread of 0.4% may suggest a less immediate recessionary concern, but inflation remains a factor.
Key Risks
- Significant recent price depreciation and very low Relative Strength (2.4/100), indicating a strong downtrend.
- The relatively low Fundamental Trend score of 30.4/100 suggests potential underlying fundamental weaknesses.
- Data quality is PARTIAL, with an `eps_proxy_used` flag, which may limit the comprehensiveness of the signal.